SVRA vs. KMPH, GLSI, STSA, PPBT, SYBX, BHC, RYTM, DCPH, AGIO, and AMRX
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Zevra Therapeutics (KMPH), Greenwich LifeSciences (GLSI), Satsuma Pharmaceuticals (STSA), Purple Biotech (PPBT), Synlogic (SYBX), Bausch Health Companies (BHC), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), Agios Pharmaceuticals (AGIO), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:KMPH) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.
Zevra Therapeutics has higher revenue and earnings than Savara.
Savara has a consensus target price of $9.17, indicating a potential upside of 124.12%.
Zevra Therapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
In the previous week, Savara had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Savara and 0 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.68 beat Savara's score of 0.00 indicating that Savara is being referred to more favorably in the news media.
19.4% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.1% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.1% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Zevra Therapeutics received 57 more outperform votes than Savara when rated by MarketBeat users. However, 66.06% of users gave Savara an outperform vote while only 63.07% of users gave Zevra Therapeutics an outperform vote.
Savara has a net margin of 0.00% compared to Savara's net margin of -328.56%. Savara's return on equity of -16.12% beat Zevra Therapeutics' return on equity.
Summary
Savara beats Zevra Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
